Automated Accounts Payable provider Glantus Holdings raises 14M and successfully floats on AIM. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

UPDATE 1-US expects over 1 mln antibody doses from Regeneron, Lilly in 2020

Fri, 9th Oct 2020 17:42

(Adds details throughout)

NEW YORK, Oct 9 (Reuters) - The U.S. government expects to
be able to provide at no cost more than 1 million doses of
antibody treatments for COVID-19 similar to the one President
Donald Trump received to treat his illness, according to a top
U.S. health official on Friday.

The government's Operation Warp Speed program currently has
"a couple of hundred thousand doses" of the monoclonal antibody
treatments being developed by drugmakers Regeneron
Pharmaceutical Inc and Eli Lilly & Co, U.S.
Department of Health and Human Services official Paul Mango said
on a call with reporters. That would top 1 million doses by the
end of the year, he said.

Mango said that the government will allocate the treatments
to the states based on need, similar to the mechanism used with
Gilead Sciences Inc's antiviral drug remdesivir for
COVID-19.

Both companies have said the drugs were shown to work in
clinical trials and that they have submitted an emergency use
authorization to the U.S. Food and Drug Administration.

Regeneron signed a $450 million deal in July to sell
Operation Warp Speed enough doses of its antibody treatment,
REGN-COV2, to treat up to 300,000 people. Lilly has not
disclosed a deal with the program. The drugmakers were not
immediately available for comment.

(Reporting by Manas Mishra in Bengalaru and Michael Erman in
New York; writing by Caroline Humer; Editing by Chizu Nomiyama,
Kirsten Donovan)

Related Shares

More News

Friday broker round-up

(Sharecast News) - NCC Group: Canaccord upgrades to buy with a target price of 318p.

14 May 21 12:57

UK prepares to 'flex' vaccination program to tackle Indian Covid-19 variant

(Sharecast News) - UK vaccines minister Nadhim Zahawi said on Friday that the government was gearing up to "flex" its inoculation program in order to tackle the new coronavirus variant first detected in India.

14 May 21 11:16

Wednesday broker round-up

(Sharecast News) - Air Partner: Canaccord reiterates buy with a target price of 100p.

12 May 21 13:55

UPDATE: Alexion shareholders give approval for takeover by AstraZeneca

UPDATE: Alexion shareholders give approval for takeover by AstraZeneca

11 May 21 21:54

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.